50% off Premium Yearly
Cineplex IncCGX.TOCOMMENTSep 16, 2015Stock price when the opinion was issued
As of Jun 19, 2026. Market Open.
Revenue growth is coming back a bit, with lower comparables from last year helping the year-over-year figures. Its debt levels are high, with net debt of $1.9B, and a net debt/EBITDA of 6.8X. Interest costs are $137M (last 12 months) and these will likely rise a bit with higher rates. 12-month cash flow was $116M and therein lies the problem. The debt is mostly due in the next five years. With attendance back, and a decent film slate, bankruptcy is becoming less of a concern, but it is still hard to paint a really positive picture here because of the leverage.
It is somewhat cheap (0.4X forward sales), but also has a fairly high forward P/E of 20.2X. It could become a takeover target, however, we would not place a high level of probability on that at these current levels.
Unlock Premium - Try 5i Free
Cineplex remains a recovery story, and its beta of 2.88 signals more risk than usual. It rose 10% in Q1, but the chart was choppy. So, consider Cineplex a partial buy. After all, Covid didn’t kill cinema-going, as some expected, but deferred it. We still love the big screen. Read Dark horses: Nuvei, Cineplex, Boralex for our full analysis.
Technically there is some support at around $37 from 2014. When the August correction took place, it did not come down to its support, which is a positive. From a technical perspective, if it holds the support, that would be a positive sign. If it breaks below $36-$37, we are actually in trouble.